SYRE — AEGLEA BIOTHERAPEUTICS INC

Ownership history in Commodore Capital LP  ·  10 quarters on record

This page tracks every 13F SEC filing in which Commodore Capital LP reported a position in AEGLEA BIOTHERAPEUTICS INC (SYRE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
5.21% (2025 Q4)
Avg. % of fund
3.0%
First filed
2023 Q3
Last filed
2025 Q4
Quarters held
10
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 2,388,245 +400,161 +20.1% 5.21% $78.2M $32.76
2025 Q3 UNCHANGED 1,988,084 — 0% 1.63% $33.3M $16.76
2025 Q2 UNCHANGED 1,988,084 — 0% 2.10% $29.8M $14.97
2025 Q1 UNCHANGED 1,988,084 — 0% 2.36% $32.1M $16.14
6 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    SYRE price (monthly, adj. close)

Other funds also holding SYRE

As of 2025 Q4 — sorted by position size

Remedium Capital Partners, LLC 28.03% Fairmount Funds Management LLC 3Y 10.02% CAXTON CORP 3Y 7Y 6.83% VR Adviser, LLC 3Y 5.96% TANG CAPITAL MANAGEMENT LLC 3Y 7Y 3.06% Affinity Asset Advisors, LLC 3Y 2.67% B Group, Inc. 2.42% TCG Crossover Management, LLC 3Y 2.06% PERCEPTIVE ADVISORS LLC 3Y 7Y 1.79% BRAIDWELL LP 3Y 1.71%
← Back to Commodore Capital LP Holdings